European Psychiatry - Volume 33 - March 2016

524 / 812

S520 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
According to the DSM5, Somatic Symptom Disorder (SSD) is char-
acterized by somatic symptoms that are either very distressing
or result in significant disruption of functioning. These criteria
are significantly different compared with previous editions of
DSM. For example, the DSM-IV diagnosis of somatization disor-
der required a specific number of complaints from among four
symptom groups, however the SSD criteria no longer have such
a requirement. Nevertheless somatic symptoms must be signif-
icantly distressing or disruptive to daily life. Very few studies
have focussed on the influence of suffering anhedonia on the per-
ception of somatic symptoms and how this impact on Health
Related Quality of Life (HRQoL), particularly physical function-
ing. We studied the relative impact of somatic symptoms on
the social and physical functioning in depressed patients. More-
over we have explored the influence of anhedonia as measured
by the Snaith-Hamilton Anhedonia Pleasure Scale (SHAPS). We
analysed the correlations between the scores of the 8 dimen-
sions of the SF-36, the SSI-26 and the SHAPS questionnaires.
The results show a significant correlation between SSI-26 score
and physical functioning (r= –0.565; P < 0.001), role physical
(r = –0.551; P< 0.001), bodily pain (r = –0.659; P < 0.001), general
health (r= –0.534; P < 0.001), vitality (r = –0.481; P= 0.001), social
functioning (r = –0.302; P = 0.044) and mental health (r= –0.461;
P = 0.001). Additionally, SHAPS score correlates with vitality
(r= –0.371; P = 0.012), social functioning (r = –0.574; P < 0.001) and
mental health (r = –0.445; P = 0.002). The results demonstrated that
both somatic symptoms and level of anhedonia negatively corre-
late with HRQoL, suggesting a potential relationship between level
of anhedonia and some somatic symptoms. This could impact on
the diagnosis and treatment of depressed patients with somatic
symptoms and anhedonia.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV534
First evidence for glial pathology in
late life minor depression: S100B is
increased in males with minor
depression
M. Polyakova ∗, C. Sander , K. Arelin , L. Lampe , T. Luck ,
J. Kratzsch , K.T. Hoffman , S. Riedel-Heller , A. Villringer ,
P. Schoenknecht , M. Schroeter
1 Max Planck Institute for Human Cognitive and Brain Sciences,
Neurology, Leipzig, Germany
2 University of Leipzig, University clinics for psychiatry and
psychotherapy, Leipzig, Germany
3 University of Leipzig, Institute of Social Medicine-Occupational
Health and Public Health, Leipzig, Germany
4 University of Leipzig, Institute of Laboratory Medicine- Clinical
Chemistry and Molecular Diagnostics, Leipzig, Germany
5 University of Leipzig, Department of Neuroradiology, Leipzig,
Germany
6 Max Planck Institute for Human Cognitive and Brain Sciences, Day
clinic of cognitive neurology, Leipzig, Germany
∗ Corresponding author.
Minor depression is diagnosed when a patient suffers from two to
four depressive symptoms for at least two weeks. Though minor
depression is a widespread phenomenon, its pathophysiology
has hardly been studied. To get a first insight into the patho-
physiological mechanisms underlying this disorder we assessed
serum levels of biomarkers for plasticity, glial and neuronal
function: brain-derived neurotrophic factor (BDNF), S100B and
neuron specific enolase (NSE). Twenty-seven subjects with minor
depressive episode and 82 healthy subjects over 60 years of
age were selected from the database of the Leipzig population-
based study of civilization diseases (LIFE). Serum levels of BDNF,
S100B and NSE were compared between groups, and corre-
lated with age, body-mass index, and degree of white matter
hyperintensities (score on Fazekas scale). S100B was significantly
increased inmales withminor depression in comparison to healthy
males, whereas other biomarkers did not differ between groups
(P = 0.10–0.66). NSE correlated with Fazekas score in patients with
minor depression (rs = 0.436, P = 0.048) and in the whole sam-
ple (rs = 0.252, P = 0.019). S100B correlated with body mass index
(rs = 0.246, P = 0.031) and with age in healthy subjects (rs = 0.345,
P = 0.002). Increased S100B in males with minor depression, with-
out alterations in BDNF and NSE, supports the glial hypothesis
of depression. Correlation between white matter hyperintensi-
ties and NSE underscores the vascular hypothesis of late life
depression.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV535
Prevalence of depressive disorders in
andalusia: Results from the PISMA-ep
study
A. Porras Segovia ∗, L. Aguado Bailón , B. Gutiérrez Martínez ,
J. Cervilla Ballesteros
1 University Hospital San Cecilio, Mental Health Services, Granada,
Spain
2 University of Granada, Psychiatry Department, Granada, Spain
∗ Corresponding author.
Introduction Depressive disorders are the most prevalent mental
diseases and they cause a major impact in our society.
Objectives The objective of this study is to establish the preva-
lence of depressive disorders in Andalusia.
Aims The aim is to provide useful information regarding this
prevalent and disabling condition, in order to contribute to its pre-
vention and treatment.
Methods Our results proceed from the PISMA-ep study, under-
took in Andalusia. In this cross-sectional community based study,
4507 participants between 18 and 75 years of agewere interviewed
by fully trained professionals. The main diagnostic tool was the
Spanish version of the MINI Neuropsychiatric International Inter-
view.
Results Our sample consists of 4507 participants. 50.9% of them
were females. Mean age was 42.8 years. The estimated one-month
prevalence of any mood disorder was 7.9% (7.1–8.6). The estimated
one-month prevalence of major depression was 6, 4% (5.6–7.1).
The prevalence of the other measured depressive disorders were as
follows: Recurrent depressive episode: 3.7% (3.2–4.3), Melancholic
depression: 3% (2.5–3.5), Severe depressive episode with psychotic
symptoms: 1.4% (1.1–1.8).
Conclusions The PISMA-ep is the first large mental health epi-
demiological study ever developed in the largest region of Spain.
The results obtained in this region show a higher prevalence of
depressive disorders in Andalusia, when comparedwith prior stud-
ies that used a nationally representative sample (i.e. the ESEMeD
study). The reasons for this higher prevalence are yet to be explored.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV536
Aspects of quality of life in depression
M.G. Puiu ∗, M.C. Manea , I.A. Andrei ,
A.M. Cristache , A.A. Frunza , M.C. Boer , B.E. Patrichi ,
M.E. Parfene Banu , M. Manea
1 “Carol Davila” University of Medicine and Pharmacy, Psychiatry
and Psychology, Bucharest, Romania